This 2009 nested case-control study analyzed data from the UK General Practice Research Database, encompassing 165,958 patients aged ≥30 years with depression but without diabetes at baseline. Over a follow-up period, 2,243 incident diabetes cases and 8,963 matched controls were identified. The study found that recent long-term use (≥24 months)
This case report highlights a serious drug interaction between methylene blue (MB) and selective serotonin reuptake inhibitors (SSRIs), leading to toxic encephalopathy and serotonin syndrome. A patient on sertraline underwent surgery where MB was administered, resulting in postoperative neurological symptoms, including altered mental status. MB inhibits monoamine oxidase A (MAO-A),
This article discusses the potential risks of methylene blue (MB), particularly its inhibition of monoamine oxidase A (MAO A), an enzyme responsible for serotonin breakdown. This inhibition can lead to elevated serotonin levels, increasing the risk of serotonin toxicity when combined with selective serotonin reuptake inhibitors (SSRIs). Serotonin toxicity, a
This randomized controlled trial examined the effects of escitalopram, an SSRI, on sexual function in nondepressed midlife women experiencing vasomotor symptoms (VMS). Over an 8-week period, escitalopram did not significantly impact overall sexual function compared to placebo, though small reductions in lubrication (P=0.02) and a marginally nonsignificant decrease in orgasm
